Your account is not claimed yet. You can sign up with ORCID to claim your account.

Mei Qiu (M Qiu)

ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 23

Top Venues

Annals of internal medicine

Circulation. Heart failure

Endocrine

Cardiovascular drugs and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Mei Qiu, Lixin Du
Letter by Qiu and Du Regarding Article, "Sodium Restriction in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Clinical Trials". Circulation. Heart failure (2023)
Mei Qiu, Lixin Du
Letter by Qiu and Du Regarding Article, "Sodium Restriction in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Clinical Trials". Circulation. Heart failure 16 (3) (2023)
Mei Qiu, Lixin Du
Early Rhythm Control Therapy for Atrial Fibrillation in Low-Risk Patients. Annals of internal medicine 176 (5) (2023)
Mei Qiu, Lixin Du
Letter by Qiu and Du Regarding Article, "Sodium Restriction in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Clinical Trials". Circulation. Heart failure 16 (3) (2023)
Mei Qiu
Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin. Annals of internal medicine 175 (12) (2022)
Mei Qiu
Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin. Annals of internal medicine 175 (12) (2022)
Mei Qiu, Xu-Bin Wei, Wei Wei
Cardiorenal benefits of glucagon-like peptide-1 analogues vs. exendin-4 analogues in patients with type 2 diabetes: a meta-analysis based on cardiovascular outcome trials. European journal of preventive cardiology 29 (7) (2022)
Mei Qiu, Fangjun Luo, Lixin Du
Serum total and free T3 and CSF total T3 levels are significantly lower in Alzheimer Disease? Endocrine (2022)
Mei Qiu
Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Annals of internal medicine 175 (1) (2022)
Mei Qiu, Liang-Liang Ding, Miao Zhang, Hai-Rong Zhou
Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors. Diabetes & vascular disease research 18 (2) (2021)
Mei Qiu, Wei Wei, Xu-Bin Wei, Shu-Yan Liu
Updated network meta-analysis assessing the relative efficacy of 13 GLP-1 RA and SGLT2 inhibitor interventions on cardiorenal and mortality outcomes in type 2 diabetes. European journal of clinical pharmacology (2021)
Mei Qiu, Liang-Liang Ding, Ze-Lin Zhan, Shu-Yan Liu
Use of SGLT2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of SGLT2 inhibitors. Endocrine 73 (1) (2021)
Dao-Gen Yin, Liang-Liang Ding, Hai-Rong Zhou, Mei Qiu, Xue-Yan Duan
Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials. Endocrine journal 68 (6) (2021)
Mei Qiu, Liang-Liang Ding, Hai-Rong Zhou
Comparative Efficacy of Five SGLT2i on Cardiorenal Events: A Network Meta-analysis Based on Ten CVOTs. American journal of cardiovascular drugs : drugs, devices, and other interventions (2021)
Mei Qiu, Xian Zhou, Miao Zhang
Cardiorenal benefits of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes without cardiovascular and renal diseases. Diabetes, obesity & metabolism (2021)
Mei Qiu, Liang-Liang Ding, Ze-Lin Zhan, Hai-Rong Zhou
Letter to the Editor regarding the article "SGLT2 inhibitors and cardiovascular and renal outcomes: a meta‑analysis and trial sequential analysis". Heart failure reviews (2021)
Mei Qiu, Liang-Liang Ding, Ze-Lin Zhan, Hai-Rong Zhou
Meta-analysis of the effects of four factors on the efficacy of SGLT2 inhibitors in patients with HFrEF. ESC heart failure 8 (2) (2021)
Mei Qiu, Xue-Yan Duan, Dao-Gen Yin
Network meta-analysis on the efficacy and safety of upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis. International journal of dermatology 61 (1) (2021)
Li-Min Zhao, Liang-Liang Ding, Ze-Lin Zhan, Mei Qiu
Sotagliflozin Reduces HF Events in T2DM Regardless of Baseline Characteristics, Including HF, CKD and LVEF. Cardiovascular drugs and therapy 35 (5) (2021)
Li-Min Zhao, Ze-Lin Zhan, Mei Qiu
Effects of SGLT2 inhibitors on cardiovascular death and all-cause death in patients with type 2 diabetes and chronic kidney disease: an updated meta-analysis including the SCORED trial. Therapeutic advances in endocrinology and metabolism 12 (2021)
Mei Qiu, Shu-Yan Liu, Jin-Song Gu, Kai-Kai Li, Ling-Lin Li, Liang-Liang Ding
Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis. Endocrine 69 (3) (2020)
Liang-Liang Ding, F Wen, H Wang, D-H Wang, Q Liu, Y-X Mo, X Tan, Mei Qiu, J-X Hu
Osteoporosis drugs for prevention of clinical fracture in white postmenopausal women: a network meta-analysis of survival data. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 31 (5) (2020)
Mei Qiu, Liang-Liang Ding, Miao Zhang, Jin-Hao Lin, Xu-Bin Wei, Hua Huang
GLP-1RAs and SGLT2is Reduce Cardiovascular Events Independent of Reductions of Systolic Blood Pressure and Body Weight: A Meta-Analysis with Meta-Regression. Diabetes therapy : research, treatment and education of diabetes and related disorders 11 (10) (2020)

Mei Qiu.css-eqlu8i{font-size:small;padding-left:4px;} (M Qiu)

Publication Activity (10 Years)

Top Topics

Top Venues

Mei Qiu (M Qiu)